Focus launches chikungunya test in US
This article was originally published in Clinica
Focus Diagnostics has launched in the US its laboratory test for chikungunya. The PCR-based test detects the presence of chikungunya virus RNA in the blood, giving results within a day of receiving the sample. The Cypress, California company suggests that doctors use the test in conjunction with the assessment of clinical symptoms, to diagnose the disease. According to the US Centers for Disease Control and Prevention (CDC), the chikungunya virus, which caused an outbreak in Italy in 2007, has the potential to enter and spread in the US. Symptoms include fever, rash and joint pain, as well as headache, fatigue, nausea, vomiting and muscle pain. While the disease is rarely fatal, long term effects can include disabling joint pain that can persist for months.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.